Wells Fargo analyst Nathan Treybeck maintains $PROCEPT BioRobotics (PRCT.US)$ with a buy rating, and adjusts the target price from $69 to $112.
According to TipRanks data, the analyst has a success rate of 72.7% and a total average return of 39.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $PROCEPT BioRobotics (PRCT.US)$'s main analysts recently are as follows:
Procept BioRobotics provides a clinically distinct solution for individuals with enlarged prostates, who commonly experience lower urinary tract symptoms. With only an 8% current market penetration, there appears to be substantial potential for further growth in this area.
Aquablation is considered to be in the early stages of adoption, a situation anticipated to gain further support from a new product cycle. Procept is aligning with 2025 consensus estimates and is receiving generally positive feedback from physicians regarding Hydros.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
